natgillin/translations-raw huggingface dataset:
Pancytopenia, anaemia (Grade 3 - 4), leukopenia
pancitopenija, anemija (3. do 4. stopnje), levkopenija
Pancytopenia, anaemia (Grade 3 – 4), leukopenia
pancitopenija, anemija (3. do 4. stopnje), levkopenija
Pancytopenia, febrile neutropenia
pancitopenija, febrilna nevtropenija
pancytopenia, febrile neutropenia, white blood cell count decreased
pancitopenija, febrilna nevtropenija, zmanjšanje števila levkocitov
Pancytopenia, granulocytopenia
pancitopenija, granulocitopenija
Pancytopenia, leukocytosis
pancitopenija, levkocitoza
Pancytopenia, neutropenia agranulocytosis
pancitopenija, nevtropenija
Pancytopenia, neutropenia, agranulocytosis
nevtropenija, agranulocitoza
Pancytopenia, neutropenia, agranulocytosis
pancitopenija, nevtropenija, agranulocitoza
Pancytopenia, prothrombin time prolonged, international normalised ratio increased, hypoprothrombinaemia, prothrombin time shortened, granulocytosis, leukocytosis, eosinophilia, lymphocytosis, monocyte count decreased, monocyte count increased, thrombocythaemia
pancitopenija, podaljšan protrombinski čas, povečano mednarodno normalizirano razmerje, hipoprotrombinemija, skrajšan protrombinski čas, granulocitoza, levkocitoza, eozinofilija, limfocitoza, zmanjšano število monocitov, povečano število monocitov, trombocitemija
pancytopenia, thrombocytopenia2, leukopenia, anaemia
levkopenija, anemija
pancytopenia, thrombocytopenia2, leukopenia, anaemia
pancitopenija, trombocitopenija2, levkopenija, anemija
Pancytopenia,, neutropenia, agranulocytosis
pancitopenija, nevtropenija, agranulocitoza
Pancytopenia- combined low counts of white cells, red cells and platelets
Pancitopenija - skupno nizko število belih krvnih celic, rdečih krvnih celic in trombocitov
Pancytopenia1, thrombocytopenia1, anaemia aggravated1, neutropenia1
pancitopenija1, trombocitopenija1, poslabšanje anemije1, nevtropenija1
Pandemic and Prepandemic vaccines contain influenza antigens that are different from those in the currently circulating influenza viruses.
Pandemska in predpandemska cepiva vsebujejo antigene virusa gripe, ki se razlikujejo od antigenov v trenutno prisotnih virusih gripe.
Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
Adjupanrix cepivo proti pandemični gripi (H5N1) (z delci virionov, inaktivirano, z adjuvansom)
Pandemic Influenza Vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
Cepivo proti pandemični gripi (H5N1) (površinski antigen, inaktiviran, z adjuvansom)
Pandemic Influenza Vaccine (surface antigen, inactivated, adjuvanted)
Cepivo proti pandemični gripi (površinski antigeni, inaktivirani, z adjuvansom).
Pandemic Influenza Vaccine H5N1 Baxter AG has been authorised under ‘Exceptional Circumstances’.
Cepivo Pandemic Influenza Vaccine H5N1 Baxter AG je pridobilo dovoljenje za promet v „izjemnih okoliščinah“.
Pandemic Influenza Vaccine H5N1 Baxter AG is a vaccine to prevent ‘pandemic’ flu.
Pandemic Influenza Vaccine H5N1 Baxter AG je cepivo, ki se uporablja za preprečevanje pandemične gripe.
Pandemic Influenza Vaccine H5N1 Baxter AG is a ‘mock-up’ vaccine.
Pandemic Influenza Vaccine H5N1 Baxter AG je modelno cepivo.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER has been authorised under ‘exceptional circumstances’.
Cepivo PANDEMIC INFLUENZA VACCINE H5N1 BAXTER je pridobilo dovoljenje za promet v ”izjemnih okoliščinah”.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER may be used in lactating women.
Cepivo PANDEMIC INFLUENZA VACCINE H5N1 BAXTER se lahko uporablja med dojenjem.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER may make you feel dizzy or sick which may affect your ability to drive or use machines.
Cepivo PANDEMIC INFLUENZA VACCINE H5N1 BAXTER lahko povzroči omotico ali slabost, kar lahko vpliva na vašo sposobnost vožnje in upravljanja s stroji.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER should not be given at the same time as other vaccines.
Cepiva PANDEMIC INFLUENZA VACCINE H5N1 BAXTER ne uporabljajte hkrati z drugimi cepivi.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER should under no circumstances be administered intravascularly.
Cepiva PANDEMIC INFLUENZA VACCINE H5N1 BAXTER ne smete v nobenem primeru injicirati v žilo.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER suspension for injection Pandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture) I.M.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER suspenzija za injiciranje cepivo proti pandemski gripi (H5N1) (celi virioni, inaktivirano, pripravljeno v celični kulturi) i.m.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER, suspension for injection Pandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture)
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER suspenzija za injiciranje cepivo proti pandemski gripi (H5N1) (celi virioni, inaktivirano, pripravljeno v celični kulturi)
Pandemic influenza vaccine H5N1 MedImmune contains live, attenuated (weakened) influenza A virus A/Vietnam/1203/2004 (H5N1) strain.
Cepivo proti pandemski gripi H5N1 MedImmune vsebuje živ, oslabljen sev virusa gripe A, in sicer sev A/Vietnam/1203/2004 (H5N1).
Pandemic influenza vaccine H5N1 MedImmune has been given ‘conditional approval’.
Cepivo proti pandemski gripi H5N1 MedImmune je pridobilo „pogojno dovoljenje za promet“.
Pandemic influenza vaccine H5N1 MedImmune has no or negligible influence on the ability to drive and use machines.
Cepivo proti pandemski gripi H5N1 MedImmune nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Pandemic influenza vaccine H5N1 MedImmune has no or negligible influence on the ability to drive and use machines.
Cepivo proti pandemski gripi H5N1 MedImmune nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Pandemic influenza vaccine H5N1 MedImmune is a pandemic preparedness vaccine.
Cepivo proti pandemski gripi H5N1 MedImmune je cepivo za pripravljenost na pandemijo.
Pandemic influenza vaccine H5N1 MedImmune is a vaccine developed to protect children aged between 12 months and 18 years against influenza (flu) during a flu pandemic.
Cepivo proti pandemski gripi H5N1 MedImmune je cepivo, ki so ga razvili za zaščito otrok, starih od 12 mesecev do 18 let, pred gripo med pandemijo gripe.
Pandemic influenza vaccine H5N1 MedImmune is a vaccine to prevent influenza (flu) in an officially declared pandemic.
Cepivo proti pandemski gripi H5N1 MedImmune je cepivo za preprečevanje gripe v primeru uradno razglašene pandemije.
Pandemic influenza vaccine H5N1 MedImmune is administered as a divided dose in both nostrils as described below. (See also How Pandemic influenza vaccine H5N1 MedImmune is given, in section 3).
Cepivo proti pandemski gripi H5N1 MedImmune se daje kot razdeljen odmerek v obe nosnici, kot je opisano spodaj. (Glej tudi "Kako se daje Cepivo proti pandemski gripi H5N1 MedImmune" v 3. poglavju).
Pandemic influenza vaccine H5N1 MedImmune is administered as a divided dose in both nostrils.
Cepivo proti pandemski gripi H5N1 MedImmune se aplicira kot razdeljen odmerek v obe nosnici.
Pandemic influenza vaccine H5N1 MedImmune is administered as a divided dose in both nostrils.
Cepivo proti pandemski gripi H5N1 MedImmune se daje kot razdeljen odmerek v obe nosnici.
Pandemic influenza vaccine H5N1 MedImmune is available as a nasal spray.
Cepivo proti pandemski gripi H5N1 MedImmune je na voljo v obliki pršila za nos.
Pandemic influenza vaccine H5N1 MedImmune is for nasal use only.
Cepivo proti pandemski gripi H5N1 MedImmune je le za nazalno uporabo.
Pandemic influenza vaccine H5N1 MedImmune IS FOR NASAL USE ONLY.
Cepivo proti pandemski gripi H5N1 MedImmune JE SAMO ZA INTRANAZALNO UPORABO.
Pandemic influenza vaccine H5N1 MedImmune is not recommended for breast-feeding women.
Cepivo proti pandemski gripi H5N1 MedImmune ni priporočljivo za ženske, ki dojijo.
Pandemic influenza vaccine H5N1 MedImmune is similar to Fluenz Tetra (a nasal influenza vaccine containing four strains), except Pandemic influenza vaccine H5N1 MedImmune provides protection against a single influenza strain in an officially declared pandemic.
Cepivo proti pandemski gripi H5N1 MedImmune je podobno cepivu Fluenz Tetra (nosnemu cepivu proti gripi, ki vsebuje štiri seve), le da Cepivo proti pandemski gripi H5N1 MedImmune ščiti samo pred enim sevom gripe med uradno razglašeno pandemijo.
Pandemic influenza vaccine H5N1 MedImmune is supplied as a 0.2 ml suspension in a single-use nasal applicator (Type 1 glass), with nozzle (polypropylene with polyethylene transfer valve), nozzle tip-protector cap (synthetic rubber), plunger rod, plunger-stopper (butyl rubber), and a dose-divider clip.
Cepivo proti pandemski gripi H5N1 MedImmune je na voljo kot 0,2-ml suspenzija v nosniku (steklo tipa 1) za enkratno uporabo z nastavkom (polipropilen s polietilensko prehodno zaklopko), pokrovčkom za zaščito konice nastavka (sintetična guma), nosilcem bata, zamaškom bata (butilna guma) in delilno zaponko odmerka.
Pandemic influenza vaccine H5N1 MedImmune must not be injected.
Cepiva proti pandemski gripi H5N1 MedImmune se ne sme injicirati.
Pandemic influenza vaccine H5N1 MedImmune must not generally be given to children who have had a severe allergic reaction to any of the substances in the vaccine including gelatin and gentamicin or to children who have had a severe allergic reaction to eggs or egg proteins, such as ovalbumin.
Cepivo proti pandemski gripi H5N1 MedImmune se v splošnem ne sme dati otrokom, ki so imeli hudo alergijsko reakcijo na katero koli snov v cepivu, vključno z želatino in gentamicinom, ter otrokom, ki so imeli hudo alergijsko reakcijo na jajca ali jajčne beljakovine, npr. ovalbumin.
Pandemic influenza vaccine H5N1 MedImmune must only be used as a nasal spray.
Cepivo proti pandemski gripi H5N1 MedImmune se sme uporabljati le kot pršilo za nos.
Pandemic influenza vaccine H5N1 MedImmune nasal spray, suspension Pandemic influenza vaccine (H5N1) (live attenuated, nasal)
Cepivo proti pandemski gripi H5N1 MedImmune pršilo za nos, suspenzija cepivo proti pandemski gripi (H5N1) (živo, oslabljeno, nazalno)
Pandemic influenza vaccine H5N1 MedImmune nasal spray, suspension Pandemic influenza vaccine (live attenuated, nasal)
Cepivo proti pandemski gripi H5N1 MedImmune pršilo za nos, suspenzija cepivo proti pandemski gripi (živo, oslabljeno, nazalno)
Pandemic influenza vaccine H5N1 MedImmune Pandemic influenza vaccine
Cepivo proti pandemski gripi H5N1 MedImmune cepivo proti pandemski gripi
Pandemic influenza vaccine H5N1 MedImmune pandemic influenza vaccine (H5N1) (live attenuated, nasal)
Cepivo proti pandemski gripi H5N1 MedImmune cepivo proti pandemski gripi (H5N1) (živo, oslabljeno, nazalno)
Pandemic influenza vaccine H5N1 MedImmune should be used in accordance with official guidance.
Cepivo proti pandemski gripi H5N1 MedImmune je treba uporabljati v skladu z uradnimi smernicami.
Pandemic influenza vaccine H5N1 MedImmune should not be used in infants below 12 months of age because of safety concerns regarding increased rates of hospitalisation and wheezing in this population (see section 4.8).
Cepiva proti pandemski gripi H5N1 MedImmune se ne sme uporabljati pri dojenčkih, mlajših od 12 mesecev zaradi pomislekov glede varnosti zaradi večjega deleža sprejemov v bolnišnico in piskajočega dihanja pri tej populaciji (glejte poglavje 4.8).
Pandemic influenza vaccine H5N1 MedImmune vaccine virus is grown in chicken eggs.
Virus v Cepivu proti pandemski gripi H5N1 MedImmune je pridobljen v kokošjih jajcih.
Pandemic influenza vaccine H5N1 MedImmune will be administered under the supervision of a doctor, nurse or pharmacist.
Cepivo proti pandemski gripi H5N1 MedImmune boste dobili pod nadzorstvom zdravnika, medicinske sestre ali farmacevta.
Pandemic influenza vaccine H5N1 MedImmune will be given as a spray in each nostril.
Cepivo proti pandemski gripi H5N1 MedImmune boste dobili kot pršilo v vsako nosnico.
Pandemrix consists of two containers: Suspension: multidose vial containing the antigen, Emulsion: multidose vial containing the adjuvant.
Cepivo Pandemrix je na voljo v dveh vsebnikih: Suspenzija: večodmerna viala z antigenom Emulzija: večodmerna viala z adjuvansom
Pandemrix should only be used if the recommended annual seasonal trivalent/quadrivalent influenza vaccines are not available and if immunisation against (H1N1)v is considered necessary (see section 4.8).
Cepivo Pandemrix se sme uporabiti le, če ni na voljo priporočenih letnih sezonskih trivalentnih/štirivalentnih cepiv proti gripi, cepljenje proti (H1N1)v pa je potrebno (glejte poglavje 4.8).
Pandemrix was originally authorised under ‘exceptional circumstances’, because, for scientific reasons, limited information was available at the time of approval.
Zdravilo Pandemrix je prvotno pridobilo dovoljenje v „izjemnih okoliščinah“, saj so bile zaradi znanstvenih razlogov ob odobritvi na voljo le omejene informacije.
Panepistimiopolis Zografou 15771 Athens Attiki GREECE
Panepistimiopolis Zografou 15771 Athens Attiki GRČIJA
panic attack, short term memory loss, apathy, confusion, sleep disorder, libido increased
napadi panike, kratkoročna izguba spomina, apatičnost, zmedenost, motnje spanja, zvečanje libida
Panic attacks
napadi panike
Panic reaction
panična reakcija,
panic reaction, depression, affect lability, state of indifference with lack of emotion, feelings of emotional and mental discomfort, altered mood
panična reakcija, depresija, čustvena labilnost, stanje ravnodušnosti z motnjami čustvovanja, občutki čustvenega in duševnega nelagodja, nihanja v razpoloženju,
Panicb Paranoiab Psychosisb
agresijab blodnjeb
Panitumumab + FOLFIRI
Panitumumab in FOLFIRI
Panitumumab does not seem to work in tumour cells that contain mutated RAS genes.
Zdi se, da panitumumab ne deluje pri tumorskih celicah, ki vsebujejo mutirani gen RAS.
Panitumumab has been designed to attach to EGFR, which can be found on the surface of certain cells, including cells in some tumours.
Panitumumab je bil zasnovan tako, da se veže na EGFR, ki je na površini določenih celic, vključno s celicami v nekaterih tumorjih.
Panitumumab treatment was discontinued due to a statistically significant reduction in PFS in patients receiving panitumumab observed in an interim analysis.
Zdravljenje s panitumumabom so prekinili, ker je bilo na vmesni analizi ugotovljeno statistično značilno skrajšanje PFSmed bolniki, ki so dobivali panitumumab.
Panniculitis, Purpura, Skin induration, Stevens-Johnson syndrome, Pruritus
panikulitis, purpura, zatrdlina kože, Stevens-Johnsonov sindrom, pruritus
Panretin 0.1% gel Alitretinoin
Panretin 0,1 % gel Alitretinoin
Panretin belongs to a group of medicines that are related to vitamin A and known as retinoids
Zdravilo Panretin spada v skupino zdravil, ki je sorodna vitaminu A in jo imenujemo retinoidi.
Panretin contains alcohol.
Zdravilo Panretin vsebuje alkohol.
Panretin gel 0.1%
Panretin 0,1 % gel
Panretin gel is for cutaneous use and is unlikely to have an effect on one’s ability to drive or operate machines.
Zdravilo Panretin gel je namenjen uporabi na koži in nima ali ima le zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Panretin gel is indicated for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma (KS) when:
Zdravilo Panretin gel je namenjeno lokalnemu zdravljenju kožnih lezij pri bolnikih s Kaposijevim sarkomom (KS), ki je posledica AIDS, in sicer če:
Panretin gel is used to treat the skin lesions seen in patients with Kaposi’s sarcoma (a type of skin cancer) in AIDS patients.
Panretin gel se uporablja za zdravljenje kožnih lezij pri bolnikih s Kaposijevim sarkomom (vrsto kožnega raka), ki prizadene bolnike z aidsom.
Panretin is a clear yellow gel.
Zdravilo Panretin je prozoren gel rumene barve.
Panretin is a gel that contains the active substance alitretinoin.
Zdravilo Panretin je gel, ki vsebuje zdravilno učinkovino alitretinoin.
Panretin is applied twice a day to the skin lesions, using enough gel to cover each lesion with a generous coating and then leaving it to dry for three to five minutes before covering with clothing.
Zdravilo Panretin se nanese na kožne lezije dvakrat na dan, pri čemer je treba uporabiti zadostno količino gela, da je vsaka lezija izdatno namazana, ter pred ponovnim nanosom oblačil počakati tri do pet minut, da se lezije posušijo.
Panretin is contraindicated (see section 4.3) in pregnancy, as alitretinoin may cause foetal harm when administered systemically to a pregnant woman.
Zdravilo Panretin je kontraindicirano (glejte poglavje 4.3) med nosečnostjo, saj alitretinoin lahko povzroča poškodbe zarodka, kadar se sistemsko daje nosečnicam.
Panretin is unlikely to affect your ability to drive or use machines.
Le malo verjetno je, da bi zdravilo Panretin gel vplivalo na sposobnost vožnje ali upravljanja s stroji.
Panretin is used in patients with AIDS-related Kaposi’s sarcoma (KS) and is for the treatment of the KS lesions:
Zdravilo Panretin se uporablja pri bolnikih s Kaposijevim sarkomom (KS), ki se pojavi zaradi AIDS Namenjen je zdravljenju KS lezij:
Panretin must also not be used in women who are pregnant or breast-feeding and must not be used to treat lesions that are close to other skin disorders.
Prav tako se ne sme uporabljati pri nosečnicah in doječih materah ter za zdravljenje lezij, ki se nahajajo v bližini drugih kožnih obolenj.
Panretin should not be used in people who may be hypersensitive (allergic) to retinoids in general, alitretinoin, or any of the other ingredients.
Zdravila Panretin ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) retinoide na splošno, alitretinoin ali katero koli drugo sestavino zdravila.
Panretin therapy should only be initiated and maintained by specialist physicians experienced in the treatment of patients with KS.
Terapijo z zdravilom Panretin naj predpiše in nadzoruje le zdravnik specialist, ki ima izkušnje z zdravljenjem KS bolnikov.
Panretin treatment should be started and maintained by a doctor with experience in treating Kaposi’s sarcoma.
Zdravljenje z zdravilom Panretin mora začeti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem Kaposijevega sarkoma.
Panretin was compared with placebo (a dummy treatment) in two 12-week studies involving a total of 402 patients with Kaposi’s sarcoma.
Zdravilo Panretin so primerjali s placebom (zdravilom brez zdravilne učinkovine) v dveh 12-tedenskih študijah, v katerih sta skupno sodelovala 402 bolnika s Kaposijevim sarkomom.
Panretin was more effective than placebo at treating Kaposi’s sarcoma.
Zdravilo Panretin je bilo pri zdravljenju Kaposijevega sarkoma učinkovitejše od placeba.
PANTECTA Control contains the active substance pantoprazole, which blocks the ‘pump’ that produces stomach acid.
Zdravilo PANTECTA Control vsebuje zdravilno učinkovino pantoprazol, ki zavira “črpalko”, ki proizvaja želodčno kislino.
PANTECTA Control is available in Alu/Alu blisters with or without cardboard reinforcement.
Zdravilo PANTECTA Control je na voljo v Alu/Alu pretisnih omotih s kartonsko oporo ali brez nje.
Pantecta Control is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Pantecta.
Zdravilo Pantecta Control je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Pantecta.
PANTOLOC Control contains the active substance pantoprazole, which blocks the ‘pump’ that produces stomach acid.
Zdravilo PANTOLOC Control vsebuje zdravilno učinkovino pantoprazol, ki zavira “črpalko”, ki proizvaja želodčno kislino.
Pantoloc Control is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Pantoloc.
Zdravilo Pantoloc Control je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Pantoloc.
Pantoprazole and other proton-pump inhibitors (PPI) were co-administered with Pradaxa in clinical trials, and concomitant PPI treatment did not appear to reduce the efficacy of Pradaxa.
Pantoprazol in druge zaviralce protonske črpalke so dajali sočasno z zdravilom Pradaxa v kliničnih preskušanjih, ki niso izkazala, da bi sočasno zdravljenje z zaviralci protonske črpalke zmanjšalo učinkovitost zdravila
Pantoprazole is almost exclusively metabolized in the liver.
Pantoprazol se skoraj izključno presnavlja v jetrih.
Pantoprazole is converted to its active form, a cyclic sulphenamide, in the acidic environment in the parietal cells where it inhibits the H+, K+-ATPase enzyme, i. e. the final stage in the production of hydrochloric acid in the stomach.
Pantoprazol se v svojo aktivno obliko, ciklični sulfenamid, pretvori v kislem okolju parietalnih celic, kjer zavira H+, K+ ATPazni encim, to je končno stopnjo v tvorbi klorovodikove kisline v želodcu.
Pantoprazole is metabolized in the liver via the cytochrome P450 enzyme system. .
Pantoprazol se presnavlja v jetrih preko encimskega sistema citokroma P450.
pantoprazole plasma concentrations
pantoprazolovo koncentracijo v
Pantoprazole: When Pradaxa was co-administered with pantoprazole, a decrease in the dabigatran area under the plasma concentration-time curve of approximately 30 % was observed.
Pantoprazol: Pri sočasnem dajanju zdravila Pradaxa in pantoprazola se je za približno 30 % zmanjšalo območje pod krivuljo plazemske koncentracije dabigatrana v odvisnosti od časa.
PANTOZOL Control contains the active substance pantoprazole, which blocks the ‘pump’ that produces stomach acid.
Zdravilo PANTOZOL Control vsebuje zdravilno učinkovino pantoprazol, ki zavira “črpalko”, ki proizvaja želodčno kislino.
Pantozol Control is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Pantozol.
Zdravilo Pantozol Control je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Pantozol.
Papaverine (used to improve blood flow around the body)
papaverin (uporablja se za izboljšanje krvnega pretoka);
Paper cover
oranžni povezovalec
Paper foil sachets (paper/PE/alu/PE) containing 1.5 g granules per sachet in a cardboard box with 100 sachets.
Vrečke papir folije (papir/PE/alu/PE), ki vsebuje 1,5 g zrnca na vrečko v kartonasti škatli s 100 vrečk.
PAPER FOLDING BOX
ŠKATLA
Paper tab
papirna nalepka
Paper Tab
Papirni pokrov
Paper Tab Needle
Papirni pokrov Igla
papillary thyroid cancer and follicular thyroid cancer (13 November 2013)
papilarni rak ščitnice in folikularni rak ščitnice (13. november 2013)
Papillary thyroid cancer: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Papilarni rak ščitnice: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Papilloedema
edem papile
Papilloedema
edem papile vidnega živca
papilloedema, loss of visual acuity or visual field, cotton-
vidnega živca, papiloedem, zmanjšanje ostrine vida ali
Papilloma/carcinoma of the preputial/clitoral gland were noted from 30 mg/kg/day onwards, representing approximately 0.5 or 0.3 times the human daily exposure (based on AUC) at 400 mg/day or 800 mg/day, respectively, and 0.4 times the daily exposure in children (based on AUC) at
Papilome/karcinome prepucijske/klitorisne žleze so opazili pri odmerkih od 30 mg/kg/dan naprej, kar predstavlja približno 0,5-kratnik oziroma 0,3-kratnik dnevne izpostavljenosti človeka (na podlagi AUC) pri odmerku 400 mg/dan oziroma 800 mg/dan, in 0,4-kratnik dnevne izpostavljenosti otrok (na podlagi AUC) pri 340 mg/m2/dan.
Papilloma/carcinoma of the preputial/clitoral gland were noted from 30mg/kg/day onwards, representing approximately 0.5 or 0.3 times the human daily exposure (based on AUC) at 400 mg/day or 800 mg/day, respectively, and 0.4 times the daily exposure in children (based on AUC) at
Papilome/karcinome prepucijske/klitorisne žleze so opazili pri odmerkih od 30 mg/kg/dan naprej, kar predstavlja približno 0,5-kratnik oziroma 0,3-kratnik dnevne izpostavljenosti človeka (na podlagi AUC) pri odmerku 400 mg/dan oziroma 800 mg/dan, in 0,4-kratnik dnevne izpostavljenosti otrok (na podlagi AUC) pri 340 mg/m2/dan.
papular
papulozen
Papules (small skin elevations)
papule (dvig majhnega dela kože nad ravnjo kože)
Para-aminosalicylic acid has negligeable influence on the ability to drive and use machines.
Para-aminosalicilna kislina ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.